keyword
MENU ▼
Read by QxMD icon Read
search

Scaffold stent

keyword
https://www.readbyqxmd.com/read/28432385/bioresorbable-vascular-scaffolds-in-coronary-chronic-total-occlusions-revascularization-safety-assessment-related-to-struts-coverage-and-apposition-in-6-month-oct-follow-up
#1
Rosa Alba Abellas-Sequeiros, Raymundo Ocaranza-Sanchez, Ramiro Trillo-Nouche, Carlos Gonzalez-Juanatey, Jose Ramon Gonzalez-Juanatey
Beneficial properties of bioresorbable vascular scaffolds (BVS) regarding to vasomotility restoration and no caging of the vessel make them attractive devices in chronic total occlusions (CTO) revascularization. However, more evidence is needed attending to their use in this specific setting. We aim to determine feasibility and safety of BVS use in CTO revascularization attending to struts coverage and apposition, as well as re-stenosis and stent thrombosis (ST) rates. 29 BVS were deployed in 9 CTO lesions revascularization (mean J-CTO score ≥3) with an acute procedural success rate of 100%...
April 21, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/28430908/late-thrombotic-events-after-bioresorbable-scaffold-implantation-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#2
Carlos Collet, Taku Asano, Yosuke Miyazaki, Erhan Tenekecioglu, Yuki Katagiri, Yohei Sotomi, Rafael Cavalcante, Robbert J de Winter, Takeshi Kimura, Runlin Gao, Serban Puricel, Stéphane Cook, Davide Capodanno, Yoshinobu Onuma, Patrick W Serruys
Aims: To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions. Methods and Results: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp-Hartung method was used to compute odds ratios (OR) and 95% confidence intervals (CI)...
April 18, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28427593/economic-outcomes-of-bioresorbable%C3%A2-vascular-scaffolds-versus%C3%A2-everolimus-eluting-stents-in-patients%C3%A2-undergoing-percutaneous-coronary-intervention-1-year-results-from-the-absorb%C3%A2-iii-trial
#3
Suzanne J Baron, Yang Lei, Khaja Chinnakondepalli, Katherine Vilain, Elizabeth A Magnuson, Dean J Kereiakes, Stephen G Ellis, Gregg W Stone, David J Cohen
OBJECTIVES: The purpose of this study was to evaluate the economic impact of the Absorb bioresorbable vascular scaffold compared with the Xience everolimus-eluting stent in patients undergoing percutaneous coronary intervention. BACKGROUND: The ABSORB III trial (Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease) demonstrated that the Absorb scaffold was noninferior to the Xience stent with respect to target lesion failure at 1 year. Whether health care costs differ between the Absorb scaffold and the Xience stent is unknown...
April 24, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28424439/management-of-immediate-partial-bioresorbable-vascular-scaffold-stent-thrombosis
#4
Ziad Said Dahdouh, Bahaa M Fadel, Hani Al Sergani, Jehad Al Buraiki, Gilles Grollier
Bioresorbable vascular scaffold (BVS) stents have been proposed recently as an elegant technique for treatment of coronary artery disease. However, perspective that these "dissolvable" stents will replace conventional metallic stents in broad spectrum of clinical conditions and patient categories in the near future has been moderated by non-negligible incidence of stent thrombosis (ST). Mechanical factors, such as strut thickness and malapposition have been implicated in increased risk of BVS ST. Presently described is case of immediate partial BVS ST in a young male related to technical procedural problem, rather than mechanical problem...
March 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28412390/first-generation-bioresorbable-vascular-scaffolds-disappearing-stents-or-disappearing-evidence
#5
EDITORIAL
Sripal Bangalore, Elazer R Edelman, Deepak L Bhatt
No abstract text is available yet for this article.
April 12, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28412389/everolimus-eluting-bioresorbable-scaffolds-versus-metallic-everolimus-eluting-stents-meta-analysis-of-randomized-controlled-trials
#6
Sabato Sorrentino, Gennaro Giustino, Roxana Mehran, Anapoorna S Kini, Samin K Sharma, Michela Faggioni, Serdar Farhan, Birgit Vogel, Ciro Indolfi, George D Dangas
BACKGROUND: Recent evidence suggests that bioresorbable vascular scaffolds (BVS) are associated with an excess of thrombotic complications compared with metallic everolimus-eluting stents (EES). OBJECTIVE: We sought to investigate the comparative effectiveness of the FDA approved Absorb BVS versus metallic EES in patients undergoing percutaneous coronary intervention at longest available follow-up. METHODS: We searched MEDLINE, Scopus and web sources for randomized trials comparing the BVS and EES...
April 12, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28408454/bioresorbable-scaffold-the-emerging-reality-and-future-directions
#7
REVIEW
Yohei Sotomi, Yoshinobu Onuma, Carlos Collet, Erhan Tenekecioglu, Renu Virmani, Neal S Kleiman, Patrick W Serruys
In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have shown excellent clinical results. However, even the latest-generation drug-eluting stent has not managed to address all the limitations of permanent metallic coronary stents, such as the risks of target lesion revascularization, neoatherosclerosis, preclusion of late lumen enlargement, and the lack of reactive vasomotion. Furthermore, the risk of very late stent, although substantially reduced with newer-generation drug-eluting stent, still remains...
April 14, 2017: Circulation Research
https://www.readbyqxmd.com/read/28406922/3d-fabrication-and-characterization-of-phosphoric-acid-scaffold-with-a-ha-%C3%AE-tcp-weight-ratio-of-60-40-for-bone-tissue-engineering-applications
#8
Yanen Wang, Kai Wang, Xinpei Li, Qinghua Wei, Weihong Chai, Shuzhi Wang, Yu Che, Tingli Lu, Bo Zhang
A key requirement for three-dimensional printing (3-DP) at room temperature of medical implants depends on the availability of printable and biocompatible binder-powder systems. Different concentration polyvinyl alcohol (PVA) and phosphoric acid solutions were chosen as the binders to make the artificial stent biocompatible with sufficient compressive strength. In order to achieve an optimum balance between the bioceramic powder and binder solution, the biocompatibility and mechanical properties of these artificial stent samples were tested using two kinds of binder solutions...
2017: PloS One
https://www.readbyqxmd.com/read/28406183/interventional-cardiology-increased-risk-of-stent-thrombosis-with-bioresorbable-scaffolds
#9
Gregory B Lim
No abstract text is available yet for this article.
April 13, 2017: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/28402237/bioresorbable-scaffolds-versus-metallic-stents-in-routine-pci
#10
Joanna J Wykrzykowska, Robin P Kraak, Sjoerd H Hofma, Rene J van der Schaaf, E Karin Arkenbout, Alexander J IJsselmuiden, Joëlle Elias, Ivo M van Dongen, Ruben Y G Tijssen, Karel T Koch, Jan Baan, M Marije Vis, Robbert J de Winter, Jan J Piek, Jan G P Tijssen, Jose P S Henriques
Background Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI). We performed an investigator-initiated, randomized trial to compare an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in the context of routine clinical practice. Methods We randomly assigned 1845 patients undergoing PCI to receive either a bioresorbable vascular scaffold (924 patients) or a metallic stent (921 patients)...
March 29, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28400917/coronary-stenting-a-matter-of-revascularization
#11
EDITORIAL
Aldo Bonaventura, Fabrizio Montecucco, Luca Liberale
In the last few decades, the recommended treatment for coronary artery disease has been dramatically improved by percutaneous coronary intervention (PCI) and the use of balloon catheters, bare metal stents (BMSs), and drug-eluting stents (DESs). Catheter balloons were burdened by acute vessel occlusion or target-lesion re-stenosis. BMSs greatly reduced those problems holding up the vessel structure, but showed high rates of in-stent re-stenosis, which is characterized by neo-intimal hyperplasia and vessel remodeling leading to a re-narrowing of the vessel diameter...
March 26, 2017: World Journal of Cardiology
https://www.readbyqxmd.com/read/28398396/-bioresorbable-vascular-scaffolds-clinical-experience-of-the-emilia-romagna-region-italy
#12
Alberto Menozzi, Gianluca Calogero Campo, Vincenzo Guiducci, Gianni Dall'Ara, Andrea Santarelli, Paolo Sbarzaglia, Marco Balducelli, Paolo Magnavacchi, Fabio Sgura, Luciano Losi, Luigi Vignali, Gianni Casella, Luigi Steffanon, Fabio Tarantino, Francesco Saia
BACKGROUND: The bioresorbable vascular scaffold (BRS) technology constitutes the new revolution of the coronary artery disease interventional treatment. Currently, three distinct types of BRSs are available but only one, the Absorb BVS, was on the market in 2013 when the Regional Commission for Medical Devices and the Cardiology and Cardiac Surgery Commission of the Emilia-Romagna Region drew up a technical and scientific essay to provide guidance for the introduction of BRS in public and affiliated health facilities...
February 2017: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/28385555/first-experience-of-drug-coated-balloons-for-treatment-of-bioresorbable-vascular-scaffold-restenosis
#13
Mostafa Elwany, Roberto Adriano Latini, Gaetano Di Palma, Pedro Silva Orrego, Bernardo Cortese
OBJECTIVES: The aim of this study is to evaluate the role of drug-coated balloons (DCB) for the management of bioresorbable vascular scaffold (BVS) restenosis. METHODS AND RESULTS: In a series of 25 BVS restenosis discovered during systematic angiographic follow up of 246 consecutive BVS implantations at our institution, DCB was used as a primary therapeutic tool in 9 patients and 3 different types of DCB were used. Follow-up coronary angiography at 12months after DCB treatment was performed to all the patients...
March 25, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28382804/optical-coherence-tomography-guided-therapy-of-instent-restenosis-for-peripheral-arterial-disease
#14
Michael K Lichtenberg, Jeffrey G Carr, Jaafer A Golzar
Approximately 27 million people in Europe and North America currently have peripheral arterial disease (PAD)1. The endovascular treatment of stenosis or blocked peripheral arteries in PAD include percutaneous transluminal angioplasty (PTA) with or without a drug coated balloon, atherectomy (rotational, directional, orbital or laser), and stenting. The development of next generation peripheral stents and drug coated stents have led to the improved treatment of complex SFA lesions, and consequently increased their usage23...
April 4, 2017: Journal of Cardiovascular Surgery
https://www.readbyqxmd.com/read/28371505/compositions-including-synthetic-and-natural-blends-for-integration-and-structural-integrity-engineered-for-different-vascular-graft-applications
#15
REVIEW
Mozhgan Shojaee, Chris A Bashur
Tissue engineering approaches for small-diameter arteries require a scaffold that simultaneously maintains patency by preventing thrombosis and intimal hyperplasia, maintains its structural integrity after grafting, and allows integration. While synthetic and extracellular matrix-derived materials can provide some of these properties individually, developing a scaffold that provides the balanced properties needed for vascular graft survival in the clinic has been particularly challenging. After 30 years of research, there are now several scaffolds currently in clinical trials...
March 29, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28363884/thrombosis-rate-is-higher-with-bioresorbable-scaffolds-than-metallic-stents-study-finds
#16
Susan Mayor
No abstract text is available yet for this article.
March 30, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28351311/lessons-learned-regarding-handling-and-deployment-of-the-absorb-bioresorbable-vascular-scaffold-in-infrapopliteal-arteries
#17
Ramon L Varcoe, Shannon D Thomas, Richard J Rapoza, Steven Kum
PURPOSE: To describe relevant technical details with which to facilitate safe and effective use of the Absorb coronary bioresorbable vascular scaffold (BVS) in lower extremity arteries. TECHNIQUE: The Absorb BVS is a balloon-expandable, poly-l-lactide structure covered in a poly-d,l-lactide bioresorbable polymer that contains the antiproliferative drug everolimus. As a polymeric structure, it has a number of unique physical, handling, and imaging properties that may differ from metallic stents and pose a challenge to the interventionist...
March 1, 2017: Journal of Endovascular Therapy
https://www.readbyqxmd.com/read/28343607/bioresorbable-vascular-scaffold-during-st-elevation-myocardial-infarction-a-systematic-review
#18
REVIEW
Fabien Picard, Quentin de Hemptinne, Robert Avram, Hung Q Ly, Philippe L L'Allier, Jean-François Tanguay
BACKGROUND: The bioresorbable vascular scaffold (BVS) represents a novel technology designed to overcome the long-term limitations of metallic coronary stent implantation in percutaneous coronary intervention. In this context, primary percutaneous coronary intervention in ST-elevation myocardial infarction (STEMI) could be a preferred scenario for BVS implantation. Nevertheless, data on efficacy and safety are lacking in this specific subset of patients. METHODS: We conducted a systematic review to examine the safety and efficacy of BVS use in STEMI patients...
April 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28335892/hybrid-percutaneous-coronary-intervention-with-bioresorbable-vascular-scaffolds-in-combination-with-drug-eluting-stents-or-drug-coated-balloons-for-complex-coronary-lesions
#19
REVIEW
Akihito Tanaka, Richard J Jabbour, Satoru Mitomo, Azeem Latib, Antonio Colombo
Bioresorbable vascular scaffolds (BVS) have become an attractive option in the percutaneous coronary intervention field due to the potential advantages associated with the complete resorption process that occurs within a few years. However, current-generation BVS have several limitations including thicker struts, reduced radial strength, and limited expansion capability when compared with drug-eluting stents (DES). As a result, complex coronary disease often contains BVS-inappropriate/unfavorable segments...
March 27, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28320687/12-months-outcomes-after-bioresorbable-vascular-scaffold-implantation-in-patients-with-acute-coronary-syndromes-data-from-the-european-multicentre-ghost-eu-extended-registry
#20
Boris Schnorbus, Jens Wiebe, Davide Capodanno, Salvatore Brugaletta, Salvatore Geraci, Julinda Mehilli, Azeem Latib, Maciej Lesiak, Christoph Jensen, Alessio Mattesini, Thomas Münzel, Piera Capranzano, Carlo Di Mario, Christoph Naber, Aleksander Araszkiewicz, Antonio Colombo, Giuseppe Caramanno, Manel Sabate, Corrado Tamburino, Holger Nef, Tommaso Gori
AIMS: We report on the mid-term outcomes of patients undergoing percutaneous coronary intervention with bioresorbable vascular scaffolds (BVS) for the treatment of acute coronary syndromes (ACS) and compare with those of patients with stable coronary artery disease (sCAD). METHODS AND RESULTS: 1477 patients underwent implantation of one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 11 European centers and were included in the GHOST-EU registry...
March 21, 2017: EuroIntervention
keyword
keyword
117505
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"